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Background: Xq28 duplications, including MECP2 (methyl CpG-binding protein 2; OMIM 300005), have been
identified in approximately 140 male patients presenting with hypotonia, severe developmental delay/intellectual
disability, limited or absent speech and ambulation, and recurrent respiratory infections. Female patients with Xq28
duplication have been rarely reported and are usually asymptomatic. Altogether, only fifteen symptomatic females
with Xq28 duplications including MECP2 have been reported so far: six of them had interstitial duplications while
the remaining had a duplication due to an unbalanced X;autosome translocation. Some of these females present
with unspecific mild to moderate intellectual disability whereas a more complex phenotype is reported for females
with unbalanced X;autosome translocations.
Findings: Here we report on the clinical features of three other adolescent to adult female patients with Xq28
interstitial duplications of variable size, all including MECP2 gene.
Conclusions: Mild to moderate cognitive impairment together with learning difficulties and speech delay were
evident in each of our patients. Moreover, early inadequate behavioral patterns followed by persistent difficulties in
the social and communication domains, as well as the occurrence of mild psychiatric disturbances, are common
features of these three patients.
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Over the last decade, Xq28 duplications including MECP2
(methyl CpG-binding protein 2; OMIM 300005), have
been identified in approximately 140 male patients pre-
senting with hypotonia, severe developmental delay/intel-
lectual disability (DD/ID), limited or absent speech and
ambulation, and recurrent respiratory infections [1-25].
Female patients with Xq28 duplication have been rarely
reported and are usually asymptomatic. Highly skewed X-
chromosome inactivation (XCI) with preferential inactiva-
tion of the duplication-bearing X chromosome has been
usually demonstrated in their blood samples [26]. Until
recently, fifteen symptomatic females with Xq28 dupli-
cations including MECP2 had been reported. Six of
them presented with interstitial duplications while in* Correspondence: francesca.novara@unipv.it
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unless otherwise stated.the remaining cases the duplication originated by an
X;autosome translocation [3,20,24,25,27-32].
Some of these females present with unspecific mild to
moderate intellectual disability whereas a more com-
plex phenotype is reported in subjects with unbalanced
X;autosome translocations (Table 1).
Here we report on the clinical features of three other
adolescent to adult females patients with Xq28 interstitial
duplications of variable size, all including MECP2 gene, in
order to improve the knowledge about phenotype associ-
ated with this clinical condition.
Clinical report
Two out of three patients reported in this paper had a
positive family history: intellectual disability (ID) was
present in different male relatives of cases 1 and 2. The
male twin and the elder brother of case 2 were affected
by severe psychomotor delay/intellectual disability and
died at 18 months and 23 years of age respectively be-
cause of respiratory infections; facial dysmorphisms wereLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 A summary of genetic and clinical features of symptomatic female patients with MECP2 duplication reported
so far in literature and including the three cases reported herein (Group A: patients with small interstitial Xq28
duplication, Group B: Xq28 duplication due to X;autosome translocations)
Group A Group B
Age 7-21 years 18 months-19 years
Genetic features
Duplicate segment length 107.5 Kb-700 Kb 0.29 Kb-16.6 Mb (for two cases the size is
unknown but cytogenetic visible)
Inheritance de novo 4 8
Maternal 5 0
Unknown 0 1
XCI Random 6 2
Skewed 3 1
Unknown 0 6
Clinical features
Abnormal general conditions 5/9 (55%) 9/9 (100%)
Dysmorphic patterns 3/9 (33%) 9/9 (100%)
Delayed motor development 4/9 (44%) 9/9 (100%)
Abnormal language development 6/9 (67%) 9/9 (100%)
Intellectual disability 7/9 (78%) 9/9 (100%)
Mood and behaviour Affected 4/9 (44%) 1/9 (11%)
Unknown 5/9 (55%) 8/9 (88%)
Social conduct Affected 8/9 (88%) 0/9 (0%)
Unknown 1/9(11%) 9/9 (100%)
Autistic features 4/9 (44%) 0/9 (0%)
Seizures 1/8 (13%) 3/9 (33%)
Brain MRI Abnormal 0/9 (0%) 3/9 (33%)
Unknown 1/9 (11%) 6/9 (67%)
Abnormal general conditions: growth retardation, constipation, hypotonia and/or joint laxity.
Dysmorphic pattern: microcephaly, trigonocephaly, facial dysmorphisms, multiple skeletal and/or organs dysmorphisms.
Language development: either delayed or impaired during school-age and adolescence.
Intellectual disability: Group A: either mild or moderate; Group B: severe only.
Brain-MRI: cortical atrophy along with white matter involvement.
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clinical details for the carriers and patients are reported
in Figure 1.
Gestation and delivery were unremarkable in all 3 cases;
both pre- and post-natal growth were normal.
Mild signs of early psychomotor retardation and speech
delay were recorded in all children by their infancy while
feeding and sleep disturbances have been reported since
18 months of age in case 3.
By puberty, mild motor clumsiness was evident in all
of them with scarce motor fluidity and mild disturbances
of coordination along with hypotonia and joint laxity.
Presently, cognitive functions were affected in all
patients. Speech development was markedly delayed
in case 1; mild delay was observed in the remaining
two. Learning difficulties were present in all. Mild tomoderate ID was evident in all patients after
intelligence testing administration at different ages
(ID was ascertained according to WISC-R scale). In
particular case 3 revealed a decline of IQ from bor-
derline at 6 years of age to mild intellectual disability
when she was 17 years old. Deficit in adaptive behav-
iour with early behavioural disturbances were evident
in all cases (Table 2). Interestingly, behavioural pat-
terns differed among the patients, both qualitatively
and temporally. In case 1 tendency to social withdraw
was present in pre-school age lasting until adoles-
cence. Conversely, hyperactivity with attention diffi-
culties were characteristic of cases 2 and 3; some
anxiety features get started during adolescence in case
2, whereas depressive mood along with anxious traits
came out at the same age in case 3. Social conduct
Figure 1 Pedigree of the three families with clinical details for carriers and patients. The male who died at 23 years of age in family 2 has
been previous published (family 10) in Clayton-Smith et al., 2009 [9]. The healthy male in family 2 died at the age of 7 years old because of
an accident.
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in case 2 whereas it was always impaired in case 3.
None of them showed stereotyped or repetitive
behaviours.
Minor facial dysmorphic features were observed only
in cases 1 and 2: broad nasal bridge, prognatism, mild
ocular hypertelorism (Figure 2).
EEG was normal in case 1, whereas posterior slow waves
were recorded in case 3. Head-brain MRI imaging (cases 1
and 3) was normal. EEG and brain MRI were not available
in case 2.
Major clinical findings for all three patients are sum-
marized in Table 2.
Informed consent was obtained for all patients. Par-
ents of cases 1 and 2 gave permission for their photo
publication.
Results
The array-CGH showed a Xq28 duplication in all the
three female patients. Case 1: arr[hg19] Xq28(153,238,
518-153,406,174)×3 mat, case 2: arr[hg19] Xq28(152,
987,955-153,609,113)×3 mat and case 3: arr[hg19] Xq28
(chrX:153,015,806-153,405,806)×3 dn (probe positions are
referred to hg19) (Figure 3).The duplications presented different sizes: 167 Kb, 621
Kb and 390 Kb respectively. In all the cases MECP2 and
IRAK1 were included in the duplication.
X chromosome inactivation test performed on DNA
extracted from blood and saliva showed a random X in-
activation in case 1 and in her mother, who carried the
same duplication (case 1: R2/R1 = 3.1 and 2.7 in blood
and saliva respectively; mother: R2/R1 = 2 and 1.8 in
blood and saliva respectively). Case 2 was also tested to-
gether with her mother and her maternal grandmother
who were both healthy carriers of the Xq28 duplication.
The test showed a 100% skewed inactivation in blood
but a random inactivation in DNA extracted from buccal
swabs in all of them (R2/R1 = 0.39, R2/R1 = 0.45, R2/R1 =
0.6 for case 2, her mother and her grandmother respect-
ively). In case 3 the test showed a skewed X chromosome
inactivation both in blood and saliva (R2/R1 = 14,7 and
11,7 respectively). In this last case microsatellite analysis
demonstrated that the anomaly originated de novo on the
paternal X chromosome (data not shown).
Discussion
MECP2 gene, located on chromosome Xq28, encodes
for an essential epigenetic regulator of postnatal brain
Table 2 Major clinical findings for all three reported patients
Case 1 (14 years) Case 2 (21 years) Case 3 (19 years)
- two spontaneous abortions - male twin: facial dysmorphism severe
early delay; death at 18 months of age
- one maternal uncle with ID - one brother: facial dysmorphism severe
developmental delay, seizures, autistic
features, death at 23 years of age
Physical data
(at birth)
GW 40 39 40
L (cm) 49 (50 pc) Not known 51 (50 pc)
BW (g) 2400 (10 pc) 3000 (50 pc) 3780 (75 pc)
HC (cm) 36 (50 pc) Not known35 (50 pc)
Early development
Walking (months) 18 13 15
Speech onset (years) 5 (few words)→ 12 (fair) 4 3
Behaviour Difficulty of separation and isolation Hyperactivity Tantrum
School age
Neurological condition Normal Normal Normal
Learning Difficulties Difficulties Difficulties
Intelligence Moderate (IQ 41) Borderline (IQ NA) Borderline (IQ 80 when 6 years)
Communication/social
conduct
Difficulties Good Difficulties (since 3 years)
Behaviour Quiet and withdrawn Hyperactivity, attention deficit,
impulsiveness
Hyperactivity
Adolescence
Neurological condition
Motor coordination Fair Poor Fair
Hypotonia/joint laxity Yes Yes Yes
Intelligence Scarce (IQ NA) Borderline (IQ 84 when15 years) Mild (IQ 57 when17 years)
Communication/social
conduct
Difficulties Difficulties Difficulties
Behaviour Quiet and meek Hyperactive, anxious, mood disorder Anxious, depressive mood
Dysmorphic features Minor facial dymorphisms (broad
nasal bridge, prognatism, mild ocular
hypertelorism)
Minor facial dysmorphisms (broad
nasal bridge, prognatism)
None
Diagnostics
EEG Normal NA Posterior slow waves
MRI Normal NA Normal
GW: gestational age; L: length; BW: body weight; HC: head circumference; IQ: intelligence quotient (ascertained according to WISC-R scale); ID: intellectual
disability; NA: not ascertained.
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had been identified as the cause of Rett syndrome,
mainly affecting females [34] and initially thought to
be lethal in males [22]. Duplications involving MECP2
have been frequently identified in male patients pre-
senting with a different phenotype from that of Rett
syndrome and mainly characterized by severe mental
retardation, recurrent respiratory infections, epilepsy, cere-
bellar degenerative change and progressive encephalopathy[4-6,8,12,14,24]. Whereas the phenotypic effect of MECP2
duplications has already been well documented in males,
the clinical implications determined by these rearrange-
ments is still poorly known in females. So far, females
with both small intrachromosomal duplications includ-
ing MECP2 [20,24,29,32] (Figure 3) and large Xq28 du-
plications resulting from an unbalanced X;autosome
translocation have been documented [3,25,27,28,30-32].
In the latter cases (Table 1, group B cases) a more severe
Figure 2 Pictures of case 1 when she was 14-years-old (A and B) and case 2 at 21 years of age (C and D).
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language development and delayed motor development
is present in all of them. Moreover epilepsy and abnor-
mal brain MRI are reported in 33% of X;autosome
translocation cases, while autistic features are absent in
all of them. This more severe phenotype is likely to be
due to the partial monosomy for the portion of the
autosome where the Xq was transposed.
Thus, MECP2 is the primary dose-sensitive and critical
gene responsible for neurological phenotypes both in
males and females. In male mice, the overexpression of
Mecp2 causes a progressive neurological disorder, includ-
ing motor dysfunction, hypoactivity, tremor, ataxia, and
premature death; ubiquitous elevated expression also led
to lethal heart and skeletal malformations [35,36].Here we described three further female patients carrying
a submicroscopic Xq28 duplication involving MECP2
(Figure 3). Two of them carried a familial Xq28 duplica-
tion, but in both cases their mothers did not present any
pathological phenotype. Differences in XCI patterns have
been hypothesize as responsible for the different pheno-
types and outcome in this chromosome imbalance. It is
reasonable to assume that the random XCI is the crucial
point leading to the intellectual disability phenotype in
symptomatic patients, whereas a highly skewed XCI with
a preferential inactivation of the duplicated X chromo-
some is a protective factor.
Our experiments to test the X chromosome inactivation
did not reveal any difference between mother and daughter
in cases 1 and 2. Those data did not explain the phenotypic
Figure 3 Schematic representation of Xq28 region. All nine female patients with intrachromosomal Xq28 duplication are represented. Familiar
cases are in black, while de novo duplications in grey. Gene content of the region is shown from the UCSC Genome Browser version Human
February 2009 (hg19).
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both in cases 1 and 2. However, it is likely that in symp-
tomatic patients the duplicated chromosome X was prefer-
entially active during the critical stages of embryonic
development thus impairing the normal brain develop-
ment. Moreover, we tested only blood and saliva and we
could not determine the X inactivation status of other
tissues.
Despite the different sizes of the identified duplicated
regions, IRAK1 was included within each of them. Dupli-
cation of this gene has been hypothesized to be respon-
sible for the severe and recurrent respiratory infections in
duplicated males [13]. This feature, that is the main cause
of death in males, has been rarely reported in female pa-
tients [24 patient 1,28,29 patient 1,32 patients 1, 2, 3 and
5] and was absent in all the three cases reported herein.
Mild to moderate cognitive impairment together with
learning difficulties and speech delay were evident in
each of our patients. It is noteworthy that the patient 3,
with de novo microduplication, presented with an appar-
ent disease progression, as shown by the mildly declined
score of her cognitive abilities (see Table 2). Similarly
MECP2 mutations in Rett syndrome females lead to a
gradual loss of acquired skills around the first year of
age [37], associated with postnatal microcephaly, a fea-
ture not present in MECP2 duplicated females.
In the only patient (case 3) with de novo Xq28 micro-
duplication, the anomaly originated on the paternal X
chromosome. Similarly, a paternal origin was demon-
strated in other two females with de novo Xq28 interstitial
duplications [32] in agreement with the X chromosome
vulnerability at male meiosis [38].
Early inadequate behavioral patterns followed by persist-
ent difficulties in the social and communication domains,
as well as the occurrence of mild psychiatric disturbancesare common features of these three patients. Hyperactivity
with attention deficit was reported in 2 out of three pa-
tients during school age, whereas symptoms such as
anxiety, or a depressive mood developed during the ado-
lescence. The occurrence of behavioural changes, as well
as the onset of psychiatric disturbances during the adoles-
cence, is a common event in children affected by mild dif-
ficulties (such as our three cases) and it can be related to
their social difficulties. None of them developed autistic
features as described in other female patients affected by a
similar condition [29, 32 case 4].
Conclusion
In conclusion we could not highlight the reason for differ-
ences in the phenotypes of MECP2 duplicated females:
neither the size of the duplication nor the X-inactivation
pattern as assessed in blood or other easy available tissues,
may predict the outcome of these subjects. This highly
variable clinical presentation makes genetic counseling
difficult in terms of prognosis, especially in prenatal cases.
Methods
Written informed consent was obtained from the par-
ents of the patients for publication of this manuscript
and any accompanying images.
Molecular karyotyping
Molecular karyotyping was performed by using the Agi-
lent array 180 K (Human Genome CGH Microarray,
Agilent Technologies, Santa Clara, CA, USA) for all pa-
tients according to the manufacturer’s protocol. Data
analysis was performed using Agilent Genomic Work-
bench Standard Edition 6.5.0.58.
Probe positions are referred to hg19.
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The X-chromosome inactivation (XCI) patterns were
analyzed for all patients by genotyping the CAG repeats
in the androgen receptor gene. 1 μg of DNA (extracted
from blood or saliva) was digested at 37°C overnight
with HpaII restriction enzyme (New England Biolabs,
Beverly, MA, USA) in a total volume of 50 μl containing
5 μl buffer 10× and 2 μl of enzyme (5 U/μl). After diges-
tion the enzyme was inactivated at 65°C, and PCR was
performed on 200 ng digested/undigested DNAs with
specific primers for HUMARA locus. One of the primer
set was labeled with the fluorescent dye (FAM). The
PCR mixture contained 10× Taq reaction buffer (200
mM Tris pH 8.4, 500 mM KCl), 50 mM MgCl2, dNTPs
(2 mM), primers (20 μM), 2.5 units of Taq polymerase
(Invitrogen, Carlsbad, CA, USA) for a final volume of
50μl. Amplification was carried out in a temperature cy-
cler with the following PCR cycling profile: preheating
at 95°C for 5 min, followed by 95°C for 45 sec, 60°C for
30 sec, 72°C for 30 sec for 28 cycles, and a final exten-
sion at 72°C for 7 min. The PCR samples were loaded
onto a 2% agarose gel, stained with ethidium bromide,
and directly visualized under ultraviolet (UV) illumin-
ation. Analysis of fluorescent samples was performed
using ABI 3100 Genetic Analyzer (Applied Biosystems).
Because CAG repeats site and the methylation sites of
the androgen receptor gene were included in the PCR frag-
ments, PCR products could only be obtained from the un-
digested DNA derived from the inactive X-chromosome.
Analysis of PCR amplicons was performed using ABI 3100
Genetic Analyzer (Applied Biosystems) to determine the
PCR product size and obtain peak areas. Finally, the XCI
patterns were classified as random (a ratio higher than
20:80 and lower than 80:20) or skewed (higher than 80:20
or lower than 20:80) according to Allen et al., 1992 [39].Microsatellite analysis
Genotyping of polymorphic loci in the patients with de
novo Xq28 duplications and in her parents was performed
by amplification with primers labeled with fluorescent
probes (ABI 6-Fam and 8-Hex), followed by analysis on
ABI 3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA). Primers were designed using the database
tool Tandem Repeats Finder (http://tandem.bu.edu/trf/
trf.intermediate.submit.html).Abbreviations
MECP2: Methyl CpG-binding protein 2; ID: Intellectual disability;
EEG: Electroencephalogram; MRI: Magnetic resonance imaging;
PCR: Polymerase chain reaction; array-CGH: Array comparative genomic
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